Presentation with acute coronary syndromes (ACS) constitutes a high-risk subset of patients with worse outcome after percutaneous coronary intervention. We report clinical outcomes in subjects with ACS from the BIOFLOW V trial (BIOTRONIK -A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions) comparing an ultrathin strut (60 μm) bioresorbable polymer sirolimus-eluting stent (BP-SES) with a thin strut (81 μm) durable polymer everolimus-eluting stent (DP-EES).
P
ercutaneous coronary intervention (PCI) is the recommended treatment for all patients with acute coronary syndromes (ACS), comprising ST-segmentelevation myocardial infarction (STEMI), non-STEMI, or high-risk unstable angina. 1, 2 Contemporary guidelines advocate revascularization with drug-eluting stents (DES) over bare metal stents for this purpose, 1,2 a recommendation supported by data demonstrating superior cardiovascular outcomes with DES. [3] [4] [5] With advancement and further modifications in DES technology, stents are now constructed with improved alloys and stent design, including thinner stent struts, in addition to enhanced polymer biocompatibility, including bioresorbable polymer (BP) technology. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Despite these advancements, until the recent BIOFLOW V study (BIOTRONIK -A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions), all previous trials showed only similarity in rates of major adverse cardiovascular events in noninferiority designed trials comparing BP stents and durable polymer (DP) DES. [13] [14] [15] [16] [17] [18] [19] [20] The recently published BIOFLOW V 21 was an international, 2:1 randomized trial comparing an ultrathin strut, bioresorbable polymer sirolimus-eluting stent (BP-SES) with a DP everolimus-eluting stent (DP-EES) about the primary end point of 12-month target lesion failure (TLF). This is the first large, randomized trial to demonstrate improved outcomes of any DES over DP-EES. The 1-year occurrence of TLF and target vessel (TV)-related MI was significantly lower among patients treated with BP-SES compared with DP-EES. Further, in pooled analysis with prior randomized trials, BP-SES demonstrated unequivocal noninferiority to DP-EES by Bayesian analysis for the outcome of TLF at 12 months. An interaction analysis between subgroups and TLF at 12 months within the BIOFLOW V study indicated ACS may benefit from BP-EES versus DP-EES. 21 Effects of BP-SES versus DP-EES are investigated further in this post hoc retrospective analysis of the ACS subgroup within the BIOFLOW V study, representing a growing population, in which early invasive strategy has been proven and is advised.
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METHODS
Study Design and Participants
BIOFLOW V was a prospective, randomized, single-blinded multicenter trial comparing the Orsiro BP-SES stent (60 μm; Biotronik, Bülach, Switzerland) and the Xience DP-EES (81 μm; DP-EES; Abbott Vascular, Santa Clara, CA) in patients undergoing elective and urgent PCI in 90 hospitals in 13 countries. Patients were randomized to BP-SES or DP-EES in a 2:1 fashion. The trial was designed with guidance from the US Food and Drug Administration and was intended to support US device approval. The detailed trial design has been previously published. 21 In brief, patients aged 18 years or older with ischemic heart disease undergoing planned stent implantation in de novo native coronary lesions were eligible for enrolment. Enrolment criteria permitted treatment of no more than 3 coronary artery lesions in a maximum of 2 native TVs. Patients with non-ST-segment-elevation ACS (including non-STEMI) without hemodynamic instability were eligible for enrolment. Angiographic inclusion criteria included a reference vessel diameter between 2.25 and 4.0 mm with lesion length 36 mm or shorter by visual estimation. Principal angiographic exclusions included chronic total occlusions, bifurcations involving a side branch with diameter of >2.0 mm, bypass graft stenosis, and DES in-stent restenosis. Calcified lesions requiring atherectomy were permitted after instances of inadequate angioplasty balloon predilation. Patients with STEMI in the past 72 hours, left ventricular ejection fraction of <30%, active stent thrombosis, creatinine clearance of <30 mL per minute, any previous PCI within 9 months or within 30 days involving the TV, and those unlikely to adhere to dual antiplatelet therapy were also excluded. The study was approved by the institutional review board or ethics committee at each enrolling site, and consecutive, eligible patients provided written informed consent before the interventional procedure.
WHAT IS KNOWN
• Improvements on the current generation drugeluting stent (DES) technology include reduced strut thickness and composition, bioresorbable polymerbased DES, polymer-free DES, and bioresorbable scaffolds.
• Until the recent BIOFLOW V study, all previous trials showed only similarity in rates of major cardiovascular events in noninferiority designed trials comparing bioresorbable polymer DES and durable polymer DES.
WHAT THE STUDY ADDS
• Our study found that the 1-year occurrence of target lesion failure and target vessel-related myocardial infarction were significantly lower with bioresorbable polymer SES compared with durable polymer EES. There were similar rates of cardiac death and clinically driven target lesion revascularization but lower rates of target vessel-related myocardial infarction and spontaneous target vessel myocardial infarction.
• Our results support the safety and efficacy of this bioresorbable polymer SES in a complex patient population with acute coronary syndromes undergoing percutaneous coronary intervention, as well as improved outcomes compared with best in class durable polymer everolimus-eluting stent.
• Our data are in line with a recent meta-analysis that found that in patients undergoing percutaneous coronary intervention, newer-generation ultrathin strut DES further improve 1-year clinical outcomes compared with contemporary thicker strut second-generation DES.
ACS was defined as subjects with unstable angina or any elevated cardiac enzymes at baseline (any preprocedure creatine kinase, creatine kinase-myocardial band, or troponin above upper normal limit). Unstable angina was defined according to the 2002 American College of Cardiology/ American Heart Association guidelines update for the management of patients with unstable angina and non-STEMI. 22 A flow chart for enrolled patients is presented in Figure 1 . This trial is registered. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results.
Device Description
The Orsiro stent is constructed of a 60-μm strut thickness cobalt alloy platform with a surface coating layer of amorphous silicon carbide. The polymer excipient is poly-L-lactic acid with asymmetrical maximal thickness on the abluminal stent surface of 7.5 and 3.5 µm on the luminal aspect. The antiproliferative drug sirolimus is present within the polymer at a concentration of 1.4 µg/mm 2 . In preclinical studies, >80% of the drug is eluted from the stent over a 90-day period, although negligent (<2%) tissue concentrations of drug are measurable in surrounding vascular tissue at 12 months. BP-SES was available in diameters ranging from 2.25 to 4.0 mm and in lengths from 9 to 40 mm. The comparator DP-EES (Xience Prime or Xience Expedition; Abbott Vascular, Santa Clara, CA) has a strut thickness of 81 µm and was available in diameters between 2.25 and 4.0 mm and in lengths ranging from 8 to 38 mm.
Data Management
All data were submitted to a central data coordinating facility The sponsor funded the study and participated in site selection and management. An independent group was solely responsible for study and site management, monitoring, and data collection (Baim Institute for Clinical Research, Boston, MA). The authors had unrestricted access to the data and are responsible for the analyses and drafting of the article.
Study End Points and Definitions
The primary end point was TLF at 12 months, defined as the composite of cardiovascular death, TV-related MI, or ischemia-driven target lesion revascularization. Secondary clinical safety and efficacy end points included major adverse cardiac events (all-cause death, MI. or ischemia-driven target lesion revascularization); TV failure (all-cause death, TV-related MI, or ischemia-driven TV revascularization); the individual components of the composite end points at 30 days and 12 months; and definite or probable stent thrombosis according to Academic Research Consortium criteria. 24 Device success was defined as achievement of <30% diameter stenosis of the target lesion with the assigned study stent, and procedure success was defined as a final diameter stenosis <30% with the assigned stent and with no in-hospital major adverse cardiovascular event.
Periprocedural MI was defined according to a protocoldefined modified Academic Research Consortium criteria 24 : creatine kinase-myocardial band, if available, or troponin measured within 48 hours of the interventional procedure elevated >3× above the upper limit of normal. Patients with baseline creatine kinase-myocardial band (or troponin) values more than the upper limit of normal, additionally had to have a confirmed rise of ≥50% than the baseline value with evidence that the cardiac biomarker values were decreasing before the suspected MI (Table I in the Data Supplement). Spontaneous MI was defined as any creatine kinase-myocardial band or troponin elevation above upper limit of normal with associated ischemic symptoms, new electrocardiographic abnormalities suggestive of ischemia or new development of imaging evidence of infarction or regional wall motion abnormalities (Table II in the Data Supplement). Ischemia-driven revascularization was identified as any repeat revascularization of the target lesion or TV associated with either (1) ischemic symptoms, an abnormal functional study, or both and a ≥50% coronary stenosis by quantitative angiography or (2) any revascularization of a ≥70% diameter stenosis. Cardiovascular death was considered any death because of any proximate cardiac cause, unwitnessed death, or death of unknown cause.
Statistical Analysis
Baseline characteristics of study patients were presented as frequencies and percentages for categorical variables and mean (SD) for continuous variables. Treatment differences on categorical variables were evaluated using Fisher exact tests. Wilson method was used to calculate the 95% CIs unless otherwise stated. Continuous variables were compared between treatments using 2-sample t tests. Time to event variables were compared between treatments using log-rank test and associations represented graphically using Kaplan-Meier curves. Associations of lesion level characteristics with treatment assignment were tested using generalized estimating equations models, in which subject was used as a clustering variable; the compound symmetry working correlation structure was used in these evaluations. Univariable logistic regression was used to evaluate association between baseline patient characteristic and 12 months TLF. Variables significantly associated with the primary outcome in univariate analyses were then included in a multivariable logistic regression. Alternatively, Cox univariable and multivariable regressions were also used to evaluate the association of TLF outcome expressed as time to event rather than as dichotomous outcome. The results were similar and included in the Data Supplement. Analyses were done using SAS (version 9.4) unless otherwise noted. We calculated proportions using known non-missing values. A P value of 0.05 was considered statistically significant.
RESULTS
Patient Enrollment and Characteristics
Between May 8, 2015 and March 31, 2016, 4772 patients were screened at 90 hospitals in 13 countries in Asia, Europe, Israel, and North America. Of these patients, 1334 were enrolled and randomized and 677 (50.7%) of them were diagnosed with ACS and comprise the population of the current analysis. In this subset, 454 (67%) were treated with the Orsiro BP-SES and 223 (33%) with the Xience DP-EES (Figure 1 ).
The BP-SES patients were more overweight with no difference about prevalence of diabetes mellitus or hyperlipidemia (Table 1) . There was no difference in lesion characteristics apart from number of diseased vessels (Table 1) . Modest but statistically significant increases in total number of stents per patient and stent length were present in the DP-EES cohort (Table 2) .
Procedural and Clinical Outcomes
There was no difference in acute lesion and device success (Table 2) . However, the overall index procedural success was significantly higher with BP-SES (94.7% versus 89.7%; P=0.023) principally driven by a higher incidence of in-hospital MI associated with DP-EES treatment ( †Ischemic status assessed by investigator as stable, but patients had elevated cardiac enzymes at baseline. ‡Patients had elevated cardiac enzymes at baseline. Various groups were examined by univariable and multivariable analyses in the ACS subgroup. Table 5 lists the multivariable predictors of TLF at 12 months. Unstable angina was associated with an increased risk of TLF compared with elevated cardiac enzymes at baseline (odds ratio, 5.57; P=0.019) as was documented silent ischemia versus elevated cardiac enzymes at baseline (odds ratio, 7.39; P=0.034), DP-EES versus BP-SES (odds ratio, 1.85; P=0.044) and number of stents implanted (per patient; odds ratio, 1.36; P=0.048). Similar results were obtained when comparing time to TLF during the first 12 months of the study (Table IV in the Data Supplement). At 12 months Kaplan-Meier estimates of the incidence of TLF were 5.4% for BP-SES versus 10.4% for DP-EES (P=0.14; Figure 2 ). KaplanMeier estimates for the incidence of protocol-defined TV-MI at 12 months was 3.3% for BP-SES versus 9.0% for DP-EES (P=0.002).
DISCUSSION
In this post hoc analysis of the ACS subgroup from the BIOFLOW V trial, the 1-year occurrence of TLF and TV-related MI was significantly lower with BP-SES compared with DP-EES. In the ACS subgroup, the absolute difference between the 2 stents was even greater than for the overall BIOFLOW V study. TV failure in ACS was 5.6% for BP-EES and 11% for DP-SES while in the entire trial it was 6.4% and 9.6%, respectively.
There was no difference at 1 year in death or in clinical target revascularization rates. The rate of stent thrombosis was extremely low and not different between the groups in spite of being an ACS population. Thus, the difference is explained by the increase in MI for the DP-EES group, with most of this difference because of periprocedural MI but also because of spontaneous MI occurring during the first year of follow-up. These results support the safety and efficacy of this ultrathin strut BP-SES in complex ACS patients.
First generation DES Cypher and Taxus were made from stainless steel and required thick struts (140 and 132 μm, respectively) for adequate radial strength and radio-opacity. Second-generation DES, which have better outcomes, use alloys, such as cobalt chromium, platinum chromium, or cobalt nickel, which allow for thinner struts (80-90 μm) with preserved radial strength and radio-opacity. Thinner struts are associated with greater flexibility and deliverability and cause less turbulence and areas of low shear, with decreased thrombogenicity. 25 They also reduce stent-induced arterial injury and inflammation and facilitate faster endothelialization. As a result, there is a 40% to 80% reduction in both procedural and late-term TV-MI compared with thick strut first generation DES. 26 Thinner struts have had positive effects on flow perturbations demonstrated in bench flow models. 27 The stent industry continues to try and improve on the second-generation DES technology by reducing strut thickness and composition, introducing bioresorbable polymer-based DES, polymer-free DES, and bioresorbable scaffolds. In general, the clinical outcomes with these newer technologies have at best been noninferior. Clinical event rates between BP-SES and DP-EES were similar in the large, all-comers BIOSCIENCE trial (Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularisation) 28 In a large (N=407) subgroup of patients with STEMI, treatment with BP-SES was associated with significantly lower TLF (3.3% versus 8.7%; P=0.02) with trends for lower cardiac death and TV-related MI. Protocol-defined target vessel-MI at 12 mo by Q-wave type and timing. Event percentages are raw percentages. P values for event percentage are calculated using Fisher exact test. BP-SES indicates bioresorbable polymer sirolimus-eluting stent; CK-MB, creatine kinase-myocardial band; DP-EES, durable polymer everolimus-eluting stent; MI, myocardial infarction; PCI, percutaneous coronary intervention; and ULN, upper limit of normal.
*The analysis of magnitude was based on peak CK-MB levels. Peak troponin levels were used when CK-MB was not available. †Only protocol-defined periprocedural target vessel-MIs occurring within 48 h of the index procedure were included in the magnitude analysis.
Another improvement in DES technology is ultrathin strut DES (60-65 μm) like the Orsiro DP-SES that were introduced in recent years. In the BIOFLOW V randomized trial, the 1-year occurrence of TLF and TV-related MI was significantly lower among patients treated with ultrathin strut BP-SES compared with regular second-generation DES DP-EES. Further, in pooled analysis with prior randomized trials, BP-SES demonstrated unequivocal noninferiority to DP-EES by Bayesian analysis for the outcome of TLF at 12 months. Similarly, in the merit-V trial, the BioMime ultrathin strut DES (Meril Life Sciences Pvt Ltd, Gujarat, India) had a significantly lower risk of MI (0.6% versus 4.8%; P=0.03) when compared with the XIENCE EES. In the randomized SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) (N=2525), 1-year definite stent thrombosis was significantly lower with the Orsiro BP-SES compared with the Nobori biolimus-eluting BP-DES (Terumo, Tokyo, Japan) with a stent strut thickness of 120 μm. (0.4% versus 1.2%; P=0.03). 29 Given that most of the difference in the present analysis between the stents was acute, it is unlikely to be because of the polymer coating or medications. It is thus possible that the difference in strut thickness could be responsible. The reasons for a benefit of ultrathin DES is not known, but a combination of better flexibility, easier delivery, less side branch coverage, and less inflammatory response are all theoretical considerations. If indeed the strut thickness has a role, the more bulky device with thicker struts might be more difficult to implant than a thinner-strut stent in the complex lesions that were included in this study.
The benefit of an ultrathin stent design is supported further by Bangalore et al 30 in a recent meta-analysis of 10 trials that randomized 11 658 patients and evaluated 3 newer generation ultrathin strut DES: Orsiro stent (60 μm), MiStent (64 μm), and BioMime (65 μm). When compared with thicker strut second-generation DES, newer generation ultrathin strut DES was associated with a 16% reduction in TLF (relative risk=0.84; 95% CI, 0.72-0.99) driven by less MI (relative risk=0.80; 95% CI, 0.65-0.99). Ultrathin strut DES was also associated with qualitatively lower rates of any stent thrombosis (relative risk=0.72; 95% CI, 0.51-1.01). The outcomes were consistent across the 3 ultrathin strut DES and with the different DES comparators. Of note, there was no difference in target lesion revascularization between the stents. The authors concluded that in patients undergoing PCI, newer generation ultrathin strut DES further improve 1-year clinical outcomes compared with contemporary thicker strut second-generation DES.
Our results support the safety and efficacy of this specific BP-SES in a complex patient population with ACS undergoing PCI, as well as improved outcomes compared with best in class DP-EES. Whether bioresorbable polymer DES are as safe and effective as DP-DES must be proven for each specific stent type in appropriately designed and statistically powered clinical trials. The ACS subgroup (n=264) of the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients With Coronary Artery Disease) (n=1123) prospective, multicenter, randomized, single-blind, controlled trial comparing BP-SES Ultimaster (Terumo, Japan) and DP-EES Xience found similar safety and efficacy outcomes. 31 TV failure was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a permanent polymer everolimus-eluting stent (P=0.36). There were no significant differences in cardiac death, MI, and stent thrombosis rate. Because adverse outcomes, such as stent thrombosis and MI are currently relatively rare after PCI, designing adequately powered studies may be impossible. Indeed, in the absence of supportive data to suggest superiority of all BP-DES versus DP-DES, [13] [14] [15] [16] it is plausible that in the present study the results can be explained by the presence of ultrathin struts of the tested BP-SES and not necessarily by the BP.
Caution should be applied when considering the comparative rates of low-frequency events and outcomes in subgroups. However, in multivariable analyses that adjusted for these measures, the benefit with BP-SES for TLF and TV-MI was independent of differences. Caution is also warranted in interpreting the results of this post hoc retrospective subgroup study as the sample size was calculated primarily to provide adequate statistical power for the study's primary end point. Therefore, findings should be considered hypothesis generating.
In summary, this ACS subanalysis of the BIOFLOW V international, prospective, randomized trial, endorse the safety and effectiveness of an ultrathin strut BP-SES in a complex PCI ACS population. 
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